Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

sustained-release mitomycin C hydrogel formulation UGN-102

A sustained-release (SR) reverse thermal (RT) hydrogel formulation containing the antineoplastic antibiotic mitomycin C (MMC), with potential antineoplastic activity. Upon intravesical instillation of the SR MMC hydrogel formulation UGN-102, the liquid converts into gel form and conforms to the bladder wall, allowing MMC to be deposited locally in the bladder to prevent the excretion of this chemotherapeutic agent via urinary flow. In turn, MMC alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis resulting in inhibition of tumor cell proliferation. Due to its reverse thermal-gelation properties, this gel is able to stay in a liquid state at cold temperatures, at 4 degrees Celsius, and transition to a water-soluble gel at body temperature. This allows for increased accumulation of MMC locally in the upper urinary tract which leads to increased efficacy compared to standard intravesical delivery of MMC for bladder cancer. Compared to UGN-101, in UGN-102 the strength of MMC is lower.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:intravesical mitomycin gel UGN-102
mitomycin urothelial gel UGN-102
MMC + UG-1 gel
RTGel with mitomycin C UGN-102
US brand name:Vesigel
Code name:UGN 102
UGN102
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search